Maravai LifeSciences Bolsa (NASDAQ: MRVI)

Últimas noticias sobre Maravai LifeSciences (NASDAQ:MRVI) Bolsa

Maravai LifeSciences

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences Holdings Inc

Macro Economic Events

News

Economics

China Earlier Announced 34% Tariff On All U.S. Imports Starting April 10 In Response To U.S.Tariffs Imposed By President Trump

Telsey Advisory Group analyst Dana Telsey maintains Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Market Perform and maintains $13 price target.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Market Perform on Guess, Maintains $13 Price Target

MSSA

Metal Sky Star To Be Delisted From Nasdaq After SPAC Deadline Miss, Will Move To OTC Market

HC Wainwright &amp; Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) with a Buy and maintains $4 price target.

Reiteration

VANI

HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target

Telsey Advisory Group analyst Joseph Feldman maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Outperform and maintains $1100 price target.

COST

Telsey Advisory Group Maintains Outperform on Costco Wholesale, Maintains $1100 Price Target

UTHR

United Therapeutics Corporation Says It Will Feature Clinical Data Across Its Commercial And Development Portfolio At International Society For Heart And Lung Transplantation 45th Annual Meeting And Scientific Sessions

<ul>
<li>Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation&nbsp;</li>
<li>Presentation featuring network meta-analysis of SYMBRAVO versus oral CGRPs</li>
</ul>

Biotech

Health Care

General

AXSM

Axsome Therapeutics Announced Multiple Presentations At The 2025 American Academy Of Neurology Annual Meeting

NYAX

Nayax Plans To Maintain Current Hardware Pricing For US Customers, Despite New Tariffs Imposed On Imports To US

Telsey Advisory Group analyst Dana Telsey maintains G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) with a Market Perform and maintains $30 price target.

GIII

Telsey Advisory Group Maintains Market Perform on G-III Apparel Group, Maintains $30 Price Target

<ul>
<li>Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year.</li>
<li>Approval brings AstraZeneca and Daiichi Sankyo's Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease.</li>
</ul>

Large Cap

The European Commission Approves AstraZeneca And Daiichi Sankyo's Enhertu (Trastuzumab Deruxtecan) As Monotherapy For Adult Patients With Unresectable Or Metastatic Hormone Receptor-positive, HER2-low Or HER2-ultralow Breast Cancer Who Have Received At Least One Endocrine Therapy In The Metastatic Setting And Who Are Not Considered Suitable For Endocrine Therapy As The Next Line Of Treatment

ARVN

Arvinas Says It Presented First-in-Human Data For Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, And Central And Peripheral LRRK2 Degradation

In this regimen, patients are treated with Imfinzi in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery.
&nbsp;

The European Commission Approves AstraZeneca's Imfinzi (Durvalumab) In Combination With Chemotherapy For Adults With Resectable Non-small Cell Lung Cancer At High Risk Of Recurrence And No Epidermal Growth Factor Receptor Mutations Or Anaplastic Lymphoma Kinase Rearrangements

HC Wainwright &amp; Co. analyst Ed Arce reiterates Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) with a Buy and maintains $7.5 price target.

AKBA

HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $7.5 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $220 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $220 Price Target

The most oversold stocks in the consumer discretionary sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">JAKKS Pacific Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAKK#NASDAQ">JAKK</a>)</h3>
<ul>
<li>On March 18, Small Cap Consumer Research analyst Eric Beder reiterated Jakks Pacific with a Buy and maintained a $40 price target. The company's stock fell around 15% over the past five days and has a 52-week low of $17.06.</li>
<li>RSI Value: 25.2</li>
<li>JAKK Price Action: Shares of JAKKS Pacific fell 13.9% to close at $21.36 on Thursday.</li>
<li>Edge Stock Ratings: 39.60 Momentum score with Value at 94.24. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/JAKK"><img loading="lazy" decoding="async" width="437" height="177" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035725/image-40.png" alt="" class="wp-image-857015" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035725/image-40.png 437w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035725/image-40-300x122.png 300w" sizes="(max-width: 437px) 100vw, 437px" /></a></figure>
<h3 class="wp-block-heading">Haverty Furniture Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HVT#NYSE">HVT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Feb. 24, Haverty Furniture reported fourth-quarter financial results and beat its EPS and revenue estimates. Steven G. Burdette, President and CEO, said, &#8220;Our team remained disciplined in managing our operations and executing our growth strategies, even amidst the housing slowdown. We achieved our goal of opening five net new stores in 2024, with a notable return to the Houston, TX market after approximately 40 years, where we now have two stores.&#8221; The company's stock fell around 17% over the past month and<a href="https://www.benzinga.com/quote/HVT"> has a 52-week low </a> of $17.78.</li>
<li>RSI Value: 27.1</li>
<li>HVT Price Action: Shares of Haverty Furniture dipped 13% to close at $17.88 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404">HVT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404"><img loading="lazy" decoding="async" width="925" height="828" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035823/image-1-12.png" alt="" class="wp-image-857016" style="width:554px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035823/image-1-12.png 925w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035823/image-1-12-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035823/image-1-12-768x687.png 768w" sizes="(max-width: 925px) 100vw, 925px" /></a></figure>
<h3 class="wp-block-heading">Six Flags Entertainment Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>)</h3>
<ul>
<li>On March 25, Truist Securities analyst Michael Swartz maintained Six Flags Entertainment with a Buy and lowered the price target from $56 to $52. The company's stock fell around 21% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/FUN">low of $31.33.</a></li>
<li>RSI Value: 27.7</li>
<li>FUN Price Action: Shares of Six Flags Entertainment fell 14.4% to close at $31.98 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404">FUN shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404"><img loading="lazy" decoding="async" width="900" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035927/image-41.png" alt="" class="wp-image-857017" style="width:518px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035927/image-41.png 900w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035927/image-41-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035927/image-41-768x711.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44626468/top-3-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 3 Risk Off Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

JAKK

Top 3 Consumer Stocks That Are Set To Fly This Quarter

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) with a Buy and maintains $21 price target.

PHGE

HC Wainwright & Co. Reiterates Buy on BiomX, Maintains $21 Price Target

Needham analyst Scott Berg reiterates Thryv Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) with a Buy and maintains $28 price target.

THRY

Needham Reiterates Buy on Thryv Holdings, Maintains $28 Price Target

LNZA

LanzaTech Confirms Receipt Of $0.02/Share Takeover Offer From Carbon Direct Capital, Board To Review Proposal

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) with a Buy and raises the price target from $10 to $24.

CMPX

HC Wainwright & Co. Maintains Buy on Compass Therapeutics, Raises Price Target to $24

MKTX

MarketAxess Posts Record Credit And Portfolio Trading Volumes In March And Q1 2025, Driven By 20% ADV Surge

Press Releases

Deadline Alert: Maravai LifeSciences Holdings, Inc. (MRVI) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Legal

MRVI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

MRVI INVESTORS: Kirby McInerney LLP Reminds Maravai Lifesciences Holdings, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm

The Gross Law Firm Reminds Maravai LifeSciences Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 - MRVI

DEADLINE ALERT for SMTC, QUBT, RKLB, MRVI: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Maravai LifeSciences Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before May 5, 2025 to Discuss Your Rights – MRVI

MRVI Investors Have Opportunity to Lead Maravai LifeSciences Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Penny Stocks

Small Cap

MRVI Investors Reminded of Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm

MRVI Shareholders Have Opportunity to Lead the Maravai LifeSciences Holdings, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - MRVI

Lost Money on Maravai LifeSciences Holdings, Inc.(MRVI)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

MRVI

QUBT

RKLB

SMTC

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Atlantic International Corp. - Common Stock

Atlantic International

Azenta

BioLife Solutions

Codexis

Champions Oncology

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Maravai LifeSciences

Noticias

Últimas noticias sobre Maravai LifeSciences (NASDAQ:MRVI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL